Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urokinase Dose-Escalation in Acute Ischemic Stroke
NCT07047326Recruiting
- Sponsor
- Capital Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of urokinase in ischemic stroke, sponsored by Capital Medical University. Primary endpoint: Number of participants with major response at 36 hours. Started Oct 2025; status: recruiting.
02
Drugs
urokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07047326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047326.